Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析

◆英語タイトル:Luye Pharma Group Ltd (2186) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH222570FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luye Pharma Group Ltd (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines, and modified-release dosages in the therapeutic areas of endocrinology, oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its R&D and manufacturing facilities in the US, China and Europe. The company works in collaboration with Excel Biopharm, Abpro Corp and ELPIS Biopharm for developing cell therapies, nucleic acid therapeutics, and antibodies for immuno-oncology treatments. Luye Pharma is headquartered in Yantai, Shandong, China.

Luye Pharma Group Ltd Key Recent Developments

Mar 27,2021: Rykindo® Launched! First Innovative Microsphere Formulation Independently Developed in China Brings Increased Clinical Benefits to Schizophrenia Patients through World-leading Microsphere Technology
Mar 18,2021: Luye Pharma Starts Patient Enrollment in Phase I Clinical Trials for Its Investigational Analgesic Drug LY03014
Aug 27,2020: Luye Pharma: Announcement of interim results for the six months ended 30 June
Apr 23,2020: Luye Pharma Group selects LifeSphere Signal and Risk Management to automate drug safety signal detection
Mar 27,2020: Luye Pharma continues to deliver strong growth in 2019

This comprehensive SWOT profile of Luye Pharma Group Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Luye Pharma Group Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Luye Pharma Group Ltd – Key Information
Luye Pharma Group Ltd – Overview
Luye Pharma Group Ltd – Key Employees
Luye Pharma Group Ltd – Key Employee Biographies
Luye Pharma Group Ltd – Key Operational Heads
Luye Pharma Group Ltd – Major Products and Services
Luye Pharma Group Ltd – History
Luye Pharma Group Ltd – Company Statement
Luye Pharma Group Ltd – Locations And Subsidiaries
Luye Pharma Group Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Luye Pharma Group Ltd – Business Description
Luye Pharma Group Ltd – Corporate Strategy
Luye Pharma Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Luye Pharma Group Ltd – Strengths
Luye Pharma Group Ltd – Weaknesses
Luye Pharma Group Ltd – Opportunities
Luye Pharma Group Ltd – Threats
Luye Pharma Group Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Luye Pharma Group Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Luye Pharma Group Ltd, Key Information
Luye Pharma Group Ltd, Key Ratios
Luye Pharma Group Ltd, Share Data
Luye Pharma Group Ltd, Major Products and Services
Luye Pharma Group Ltd, History
Luye Pharma Group Ltd, Key Employees
Luye Pharma Group Ltd, Key Employee Biographies
Luye Pharma Group Ltd, Key Operational Heads
Luye Pharma Group Ltd, Other Locations
Luye Pharma Group Ltd, Subsidiaries
Luye Pharma Group Ltd, Key Competitors
Luye Pharma Group Ltd, SWOT Analysis
Luye Pharma Group Ltd, Ratios based on current share price
Luye Pharma Group Ltd, Annual Ratios
Luye Pharma Group Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Idemitsu Kosan Co Ltd (5019)-エネルギー分野:企業M&A・提携分析
    Summary Idemitsu Kosan Co., Ltd. (Idemitsu) is an integrated energy company that explores, produces, refines, and sells oil and gas, lubricants, and petroleum products. Apart from petroleum products, the company also manufactures agricultural chemicals, agricultural materials, and other chemicals. I …
  • Falck Renewables S.p.A. (FKR):電力:M&Aディール及び事業提携情報
    Summary Falck Renewables S.p.A. (Falck Renewables), formerly Actelios S.p.A that develops, designs, constructs and manages energy production plants. It operates as a subsidiary of Falck S.p.A. The company produces clean energy from various renewable sources including wind energy, solar energy, bioma …
  • American Electric Power Company, Inc. (AEP)-エネルギー分野:企業M&A・提携分析
    Summary American Electric Power Company, Inc. (AEP) is a holding company that carries out the generation, transmission and distribution of electricity through its subsidiaries. The company generates electricity through various sources of energy such as coal and lignite, natural gas, nuclear, and hyd …
  • Oiltanking GmbH:石油・ガス:M&Aディール及び事業提携情報
    Summary Oiltanking GmbH (Oiltanking), a subsidiary of Marquard & Bahls AG is an independent tank storage service provider. The company offers storage facilities and associated services for oils, petroleum products, chemicals, biofuels, gases and dry bulk. It owns and operates terminals in Europe, No …
  • SKF AB:企業の戦略・SWOT・財務情報
    SKF AB - Strategy, SWOT and Corporate Finance Report Summary SKF AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Unisys Corp (UIS):企業の財務・戦略的SWOT分析
    Unisys Corp (UIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ModusLink Global Solutions, Inc. (MLNK):企業の財務・戦略的SWOT分析
    ModusLink Global Solutions, Inc. (MLNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Firmenich SA:企業の戦略的SWOT分析
    Firmenich SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fate Therapeutics Inc (FATE):製薬・医療:M&Aディール及び事業提携情報
    Summary Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidate …
  • Engie Brasil Energia SA (EGIE3):企業の財務・戦略的SWOT分析
    Engie Brasil Energia SA (EGIE3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • MDNA Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test (PCMT) based on the science of mitochondrial DNA (mtDNA) is a tissue-based prostate cancer diagnostics for prostate and o …
  • HLL Lifecare Ltd:企業の製品パイプライン分析
    Summary HLL Lifecare Ltd (HLL) is a manufacturer of natural rubber latex condoms. The company offers products such as condoms, tubal rings, synthetic braided and coated absorbable suture, monofilament polydioxanone surgical suture, synthetic absorbable surgical suture, blood bank refrigerator, steri …
  • Thirumalai Chemicals Ltd (TIRUMALCHM):企業の財務・戦略的SWOT分析
    Thirumalai Chemicals Ltd (TIRUMALCHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • IsoRay Inc (ISR):医療機器:M&Aディール及び事業提携情報
    Summary IsoRay Inc (IsoRay), formerly Century Park Pictures Corporation, is a medical technology company which develops, manufactures and markets isotope-based personalized brachytherapy products and devices for the treatment of cancer and other malignant tumors. The company produced Cesium-131, a r …
  • Evoqua Water Technologies Corp (AQUA):企業の財務・戦略的SWOT分析
    Evoqua Water Technologies Corp (AQUA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Catalyst Paper Corp:企業の戦略的SWOT分析
    Catalyst Paper Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Fate Therapeutics Inc (FATE)-製薬・医療分野:企業M&A・提携分析
    Summary Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidate …
  • Air Water Inc (4088):企業の財務・戦略的SWOT分析
    Air Water Inc (4088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Beckman Coulter Inc-医療機器分野:企業M&A・提携分析
    Summary Beckman Coulter Inc (Beckman) is a manufacturer of biomedical testing instrument systems. It develops, manufactures and markets biomedical laboratory instruments, software and other things that simplify and automate complex biomedical tests. The company’s products are used in a wide range of …
  • Cyxone AB (CYXO):製薬・医療:M&Aディール及び事業提携情報
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company develops T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral ad …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆